306 related articles for article (PubMed ID: 6580490)
1. Analysis of natural killer cell cytotoxicity of cancer patients treated with recombinant interferon.
Lotzová E; Savary CA; Quesada JR; Gutterman JU; Hersh EM
J Natl Cancer Inst; 1983 Nov; 71(5):903-10. PubMed ID: 6580490
[TBL] [Abstract][Full Text] [Related]
2. Regulation of human natural killer cell cytotoxicity by recombinant leukocyte interferon clone A.
Lotzová E; Savary CA; Gutterman JU; Quesada JR; Hersh EM
J Biol Response Mod; 1983; 2(5):482-96. PubMed ID: 6644351
[TBL] [Abstract][Full Text] [Related]
3. Correlation between in vitro and systemic effects of native and recombinant interferons-alpha on human natural killer cell cytotoxicity.
Edwards BS; Hawkins MJ; Borden EC
J Biol Response Mod; 1983; 2(5):409-17. PubMed ID: 6644345
[TBL] [Abstract][Full Text] [Related]
4. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients.
Koren HS; Brandt CP; Tso CY; Laszlo J
J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332
[TBL] [Abstract][Full Text] [Related]
5. Comparative in vivo and in vitro activation of human natural killer cells by two recombinant alpha-interferons differing in antiviral activity.
Edwards BS; Hawkins MJ; Borden EC
Cancer Res; 1984 Jul; 44(7):3135-9. PubMed ID: 6586292
[TBL] [Abstract][Full Text] [Related]
6. Regulation of natural killer cytotoxicity by recombinant alpha interferons. Augmentation by IFN-alpha 7, an interferon similar to IFN-alpha J.
Platsoucas CD; Fox FE; Oleszak E; Fong K; Nanno M; Ioannides CG; Trotta PP
Anticancer Res; 1989; 9(4):849-58. PubMed ID: 2817813
[TBL] [Abstract][Full Text] [Related]
7. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy.
Spina CA; Fahey JL; Durkos-Smith D; Dorey F; Sarna G
J Biol Response Mod; 1983; 2(5):458-69. PubMed ID: 6644350
[TBL] [Abstract][Full Text] [Related]
8. In vivo priming effects of interferon-beta ser on NK activity of peripheral blood mononuclear cells in cancer patients.
Fujimiya Y; Wagner RJ; Groveman S; Sielaff K; Kohsaka T; Nakayama M
Ther Immunol; 1995 Feb; 2(1):15-22. PubMed ID: 7553067
[TBL] [Abstract][Full Text] [Related]
9. Modulation of murine natural killer cell activity in vitro and in vivo by recombinant human interferons.
Brunda MJ; Rosenbaum D
Cancer Res; 1984 Feb; 44(2):597-601. PubMed ID: 6692364
[TBL] [Abstract][Full Text] [Related]
10. Parameters of interferon action: II. Immunological effects of recombinant leukocyte interferon (IFN-alpha 2) in phase I-II trials.
Ernstoff MS; Fusi S; Kirkwood JM
J Biol Response Mod; 1983; 2(6):540-7. PubMed ID: 6607324
[TBL] [Abstract][Full Text] [Related]
11. Comparison of augmentation of human natural killer cell cytotoxicity by interferon-alpha subtypes.
Verhagen A; Mackay IR; Rowley M; Tymms M
Nat Immun Cell Growth Regul; 1990; 9(5):325-33. PubMed ID: 2077397
[TBL] [Abstract][Full Text] [Related]
12. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
[TBL] [Abstract][Full Text] [Related]
13. [Effect of interferon-alpha (MOR-22) on human NK cell activity].
Yanagihara Y; Tochizawa S; Ishii K; Hirai Y
Gan To Kagaku Ryoho; 1986 Feb; 13(2):342-8. PubMed ID: 3947110
[TBL] [Abstract][Full Text] [Related]
14. Defective NK cell activity following thermal injury.
Klimpel GR; Herndon DN; Fons M; Albrecht T; Asuncion MT; Chin R; Stein MD
Clin Exp Immunol; 1986 Nov; 66(2):384-92. PubMed ID: 3493101
[TBL] [Abstract][Full Text] [Related]
15. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon.
Maluish AE; Ortaldo JR; Conlon JC; Sherwin SA; Leavitt R; Strong DM; Weirnik P; Oldham RK; Herberman RB
J Immunol; 1983 Jul; 131(1):503-7. PubMed ID: 6863923
[TBL] [Abstract][Full Text] [Related]
16. Immunomodulation of early engrafted natural killer cells with interleukin-2 and interferon-alpha in autologous stem cell transplantation.
Porrata LF; Inwards DJ; Lacy MQ; Markovic SN
Bone Marrow Transplant; 2001 Oct; 28(7):673-80. PubMed ID: 11704790
[TBL] [Abstract][Full Text] [Related]
17. Systemic administration of human leukocyte interferon to melanoma patients. II. Cellular events associated with changes in natural killer cytotoxicity.
Golub SH; D'Amore P; Rainey M
J Natl Cancer Inst; 1982 May; 68(5):711-7. PubMed ID: 6175788
[TBL] [Abstract][Full Text] [Related]
18. Surface markers and cytotoxic activity of blood natural killer cells studied at the single cell level in Hodgkin's disease.
Jezewska E; Björkholm M; Giscombe R; Holm G; Tullgren O
Clin Exp Immunol; 1985 Jul; 61(1):96-102. PubMed ID: 4042422
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the natural killer cell-interferon system in patients with mid-gut carcinoid tumours treated with leucocyte interferon.
Funa K; Alm GV; Rönnblom L; Oberg K
Clin Exp Immunol; 1983 Sep; 53(3):716-24. PubMed ID: 6616963
[TBL] [Abstract][Full Text] [Related]
20. The different effects of recombinant human interferon-gamma and recombinant human interferon-beta on the activation of natural killer cells.
Okabe M; Gomi K; Morimoto M; Nakamizo N
Jpn J Cancer Res; 1985 Jul; 76(7):608-17. PubMed ID: 3928557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
